IX Biopharma Debt 2024

IX Biopharma Aktienanalyse

What does IX Biopharma do?

IX Biopharma Ltd is a leading biopharmaceutical company based in Singapore. The company was founded in 2007 by Dr. Jan-Olof Heldin, a globally recognized biotech entrepreneur. The history of IX Biopharma dates back to the late 90s, when Dr. Heldin began working on a new method of drug delivery called "Oral Transmucosal Technology" (OTM). This technology allows for the development of drugs that can quickly and specifically penetrate the body, with a very high bioavailability. Today, IX Biopharma has a strong presence in the market for novel OTM-based drugs. The company operates in three different business areas: human medicine products, animal health, and life sciences. IX Biopharma's human medicine products are specialized in the treatment of pain and inflammation. The company has already launched a product - a fast-acting spray for pain relief. This new technology allows the medication to quickly enter the body and take effect, providing patients with rapid pain relief. IX Biopharma is currently working on additional products based on OTM technology to provide suitable solutions for other medical conditions as well. In the animal health sector, IX Biopharma offers veterinary products tailored to the needs of pets and livestock. The company collaborates closely with veterinarians and livestock experts to develop innovative therapies and treatment methods customized for specific animal needs. In the field of life sciences, IX Biopharma engages in a wide range of activities and services. These include the development of diagnostic products, conducting clinical trials, identifying biomarkers, and developing immunotherapies. Overall, IX Biopharma is an innovative biopharmaceutical company specializing in the development of drugs based on new technologies. The company is constantly striving to find innovative solutions to improve the health of humans and animals. With a dedicated team of scientists and researchers, as well as a strong presence in Asia and Europe, IX Biopharma is a pioneer in the new world of OTM-based drug development. IX Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding IX Biopharma's Debt Structure

IX Biopharma's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing IX Biopharma's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to IX Biopharma’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in IX Biopharma’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about IX Biopharma stock

What is the debt of IX Biopharma this year?

IX Biopharma has a debt level of -2.18 SGD this year.

What was the debt of IX Biopharma compared to the previous year?

The debt of IX Biopharma has increased by -76% compared to the previous year dropped.

What are the consequences of high debt for investors in IX Biopharma?

High debt can pose a risk for investors of IX Biopharma, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of IX Biopharma?

Low debt means that IX Biopharma has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from IX Biopharma affect the company?

An increase in debt of IX Biopharma can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of IX Biopharma affect the company?

A reduction in debt of IX Biopharma can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of IX Biopharma?

Some factors that can influence the debt of IX Biopharma include investments, acquisitions, operating costs, and revenue development.

Why are the debts of IX Biopharma so important for investors?

The debts of IX Biopharma are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can IX Biopharma take to change the debt?

To change the debt, IX Biopharma can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does IX Biopharma pay?

Over the past 12 months, IX Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IX Biopharma is expected to pay a dividend of 0 SGD.

What is the dividend yield of IX Biopharma?

The current dividend yield of IX Biopharma is .

When does IX Biopharma pay dividends?

IX Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IX Biopharma?

IX Biopharma paid dividends every year for the past 0 years.

What is the dividend of IX Biopharma?

For the upcoming 12 months, dividends amounting to 0 SGD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IX Biopharma located?

IX Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von IX Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IX Biopharma from 7/5/2024 amounting to 0 SGD, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did IX Biopharma pay the last dividend?

The last dividend was paid out on 7/5/2024.

What was the dividend of IX Biopharma in the year 2023?

In the year 2023, IX Biopharma distributed 0 SGD as dividends.

In which currency does IX Biopharma pay out the dividend?

The dividends of IX Biopharma are distributed in SGD.